State Street Corp Denali Therapeutics Inc. Transaction History
State Street Corp
- $2.8 Trillion
- Q3 2025
A detailed history of State Street Corp transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 5,464,261 shares of DNLI stock, worth $95.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,464,261
Previous 4,517,994
20.94%
Holding current value
$95.3 Million
Previous $63.2 Million
25.53%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding DNLI
# of Institutions
259Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.64MShares$98.3 Million0.05% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL5.47MShares$95.3 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...